These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10921030)

  • 21. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease.
    Tanaka T; Inoue K; Hayashi Y; Abe A; Tsukiyama-Kohara K; Nuriya H; Aoki Y; Kawaguchi R; Kubota K; Yoshiba M; Koike M; Tanaka S; Kohara M
    J Med Virol; 2004 Feb; 72(2):223-9. PubMed ID: 14695663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SEN virus infection and the risk of hepatocellular carcinoma: a case-control study.
    Tangkijvanich P; Theamboonlers A; Sriponthong M; Kullavanijaya P; Poovorawan Y
    Am J Gastroenterol; 2003 Nov; 98(11):2500-4. PubMed ID: 14638355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China.
    Fang Y; Shang QL; Liu JY; Li D; Xu WZ; Teng X; Zhao HW; Fu LJ; Zhang FM; Gu HX
    J Infect; 2009 May; 58(5):383-8. PubMed ID: 19329189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan.
    Yano Y; Yamashita F; Sumie S; Ando E; Fukumori K; Kiyama M; Oyama T; Kuroki S; Kato O; Yamamoto H; Tanaka M; Sata M
    Am J Gastroenterol; 2002 Jan; 97(1):156-61. PubMed ID: 11808941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan.
    Tsai MC; Kee KM; Chen YD; Lin LC; Tsai LS; Chen HH; Lu SN
    J Gastroenterol Hepatol; 2007 Jan; 22(1):92-8. PubMed ID: 17201888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area.
    Huang YH; Wu JC; Chen CH; Chang TT; Lee PC; Chau GY; Lui WY; Chang FY; Lee SD
    Liver Int; 2005 Apr; 25(2):236-41. PubMed ID: 15780044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma.
    Tanaka H; Iwasaki Y; Nouso K; Kobayashi Y; Nakamura S; Matsumoto E; Toshikuni N; Kaneyoshi T; Ohsawa T; Takaguchi K; Fujio K; Senoh T; Ohnishi T; Sakaguchi K; Shiratori Y
    J Gastroenterol Hepatol; 2005 Jun; 20(6):850-6. PubMed ID: 15946131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].
    Kim MJ; Kwon OS; Chung NS; Lee SY; Jung HS; Park DK; Ku YS; Kim YK; Kim YS; Kim JH
    Korean J Hepatol; 2008 Mar; 14(1):67-76. PubMed ID: 18367859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.
    Murugavel KG; Mathews S; Jayanthi V; Shankar EM; Hari R; Surendran R; Vengatesan A; Raghuram K; Rajasambandam P; Murali A; Srinivas U; Palaniswamy KR; Pugazhendhi T; Thyagarajan SP
    Int J Infect Dis; 2008 Nov; 12(6):e71-6. PubMed ID: 18658001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Distribution of hepatitis B virus genotypes and its clinical significance in Guangxi].
    Ge XM; Li DY; Fang ZL; Huang GY; Jiang SQ; Pan HD; Du Y; Wang CY; Ding X; Masashi M
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):174-9. PubMed ID: 12870004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus genotypes and the development of hepatocellular carcinoma.
    Stankovic-Djordjevic D; Djordjevic N; Tasic G; Dinic M; Karanikolic A; Pesic M
    J Dig Dis; 2007 Feb; 8(1):42-7. PubMed ID: 17261134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan.
    Taura N; Hamasaki K; Nakao K; Ichikawa T; Nishimura D; Goto T; Fukuta M; Kawashimo H; Miyaaki H; Fujimoto M; Kusumoto K; Motoyoshi Y; Shibata H; Inokuchi K; Eguchi K
    Oncol Rep; 2006 Oct; 16(4):837-43. PubMed ID: 16969503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tight association of hepatocellular carcinoma with HBV infection in North China.
    Gao JD; Shao YF; Xu Y; Ming LH; Wu ZY; Liu GT; Wang XH; Gao WH; Sun YT; Feng XL; Liang LM; Zhang YH; Sun ZT
    Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):46-9. PubMed ID: 15730918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
    Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
    J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study.
    Tanaka K; Nagao Y; Ide T; Kumashiro R; Sata M
    Int J Mol Med; 2006 May; 17(5):827-32. PubMed ID: 16596267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Previous or occult hepatitis B virus infection in hepatitis B surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma.
    Ohba K; Kubo S; Tamori A; Hirohashi K; Tanaka H; Shuto T; Nishiguchi S; Kinoshita H
    Surg Today; 2004; 34(10):842-8. PubMed ID: 15449154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
    Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
    Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of hepatitis B virus infection and inferior vena cava obstruction among patients with liver cirrhosis or hepatocellular carcinoma in Nepal.
    Shrestha SM; Shrestha S; Shrestha A; Tsuda F; Endo K; Takahashi M; Okamoto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1921-8. PubMed ID: 17914971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
    Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S
    J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.